Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cue Biopharma Inc
(NQ:
CUE
)
1.100
+0.050 (+4.76%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cue Biopharma Inc
< Previous
1
2
3
4
5
Next >
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024
May 09, 2024
CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 09, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
May 08, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Forecasting The Future: 4 Analyst Projections For Cue Biopharma
April 09, 2024
Via
Benzinga
Cue Biopharma Inc. (NASDAQ: CUE) Leading the Way in Wednesday Trading Based on Percentage Gain
March 13, 2024
Via
Investor Brand Network
Where Cue Biopharma Stands With Analysts
June 15, 2023
Via
Benzinga
Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
May 07, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
May 02, 2024
Via
Benzinga
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
April 08, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
CUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023
April 02, 2024
CUE stock results show that Cue Biopharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Cue Biopharma to Host Business Update Call and Webcast
April 02, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 13, 2024
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24...
Via
Benzinga
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
February 29, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
January 01, 2024
Via
Benzinga
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023
December 14, 2023
CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2023.
Via
InvestorPlace
Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
November 22, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 09, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
November 07, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
November 03, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Host Business Update Call and Webcast
November 02, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 27, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®
September 26, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
The Truth About IPO Investing
September 02, 2023
When most companies go public, they are somewhat mature. Tech company initial public offerings, or IPOs, are a bit different, however. These companies are often not yet profitable. And biotech IPOs are...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Cue Biopharma And 2 Other Stocks Under $3 Insiders Are Buying
August 30, 2023
The Dow Jones closed higher by close to 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 09, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Host Business Update Call and Webcast
August 02, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
3 Biotech Stocks to Buy as Companies Ink Major Deals
June 22, 2023
Pharmaceutical and biotech companies will soon face generic competition, creating big opportunity for these top biotech stocks to buy.
Via
InvestorPlace
Cue Biopharma to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual Meeting
June 14, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.